Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.50 |
| ▸ | MAOA | P21397 | 13/20 | 0.50 |
| ▸ | MAOB | P27338 | 13/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074430 | 1.00 | KDM1A (0.50) | KDM1AMAOAMAOBMAPTPOLB | |
| Hydrochloric Acid SCHEMBL2130468 | 0.98 | KDM1A (0.51) | KDM1AMAOAMAOBMAPT | |
| Hydrochloric Acid SCHEMBL2131519 | 0.98 | KDM1A (0.51) | KDM1AMAOAMAOBMAPT | |
| SCHEMBL8036140 | 0.84 | KDM1A (0.46) | KDM1A | |
| SCHEMBL12383191 | 0.84 | KDM1A (0.46) | KDM1A | |
| SCHEMBL8039426 | 0.84 | KDM1A (0.46) | KDM1A | |
| SCHEMBL903428 | 0.83 | GAA (0.53) | KDM1AMAOAMAOB | |
| SCHEMBL15767768 | 0.83 | GAA (0.53) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2072193 | 0.83 | KDM1A (0.49) | KDM1A | |
| Hydrochloric Acid SCHEMBL2072194 | 0.83 | KDM1A (0.49) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2231597-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | KDM1A 2795/4885MAOA 1604/4885MAOB 369/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | KDM1A 2795/4885MAOA 1604/4885MAOB 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.